Cancer Research AACR Membership Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burke, P. A.
Right arrow Articles by DeNardo, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, P. A.
Right arrow Articles by DeNardo, G. L.
[Cancer Research 62, 4263-4272, August 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Cilengitide Targeting of {alpha}vß3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts1

Patricia A. Burke, Sally J. DeNardo2, Laird A. Miers, Kathleen R. Lamborn, Siegfried Matzku and Gerald L. DeNardo

University of California at Davis, Sacramento Medical Center, Radiodiagnosis and Therapy/Internal Medicine, Sacramento, California 95816 [P. A. B., S. J. D., L. A. M., G. L. D.]; University of California at San Francisco, Department of Neurological Surgery, San Francisco, California 94143 [K. R. L.]; and Merck KGaA, Department of Preclinical Oncology, 64271 Darmstadt, Germany [S. M.]

Although metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemictargeted radiation modality, complete and permanent remissions are not typical with single-modality treatment. Antiangiogenic agents, which target normal, proliferating endothelial cells, have the potential to provide relatively nontoxic continuous inhibition of tumor growth by blocking new blood vessel growth and may synergize with RIT to increase efficacy. This study was designed to determine whether, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the {alpha}vß3 integrin receptor expressed on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. HBT 3477 breast cancer tumor response in nude mice was compared between groups of untreated mice (n = 24), Cilengitide-treated mice (n = 18), RIT (200–260 µCi 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide ChL6; n = 46), and combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 µg/dose; n = 41). Tumor size, survival, body weight, and blood counts were monitored for efficacy and toxicity of therapy. To clarify the mechanism of synergistic effect, tumors were evaluated at selected time points through 6 days for apoptosis, proliferation, and microvessel density. Cilengitide alone did not alter tumor growth when compared with untreated mice, but CMRIT with Cilengitide increased efficacy of treatment, with the cure rate for mice that received 260 µCi RIT increasing from 15 to 53% (P = 0.011). Lower-dose RIT (200 µCi) combined with Cilengitide resulted in less increase in cures (36 compared with 25% for RIT alone; P = 0.514). Combined analysis for high- and low-dose groups demonstrated increased efficacy of CMRIT (P = 0.020). Analysis of tumors from CMRIT mice indicated significantly increased apoptosis of tumor and endothelial cells 5 days after RIT compared with tumors from mice given RIT alone. Proliferation was decreased in CMRIT tumors compared with RIT tumors at 6 days (ANOVA, P < 0.05). Microvessel density in tumors from RIT and CMRIT mice was not different. No increased toxicity attributable to Cilengitide was observed based upon pooled blood sample and no statistical increase in mortality. In conclusion, CMRIT, combining Cilengitide and RIT, significantly increased the efficacy of therapy and increased apoptosis compared with single-modality therapy with either agent, in an aggressive, well-studied breast cancer model. The enhanced therapeutic synergy is of particular note, having been achieved without additional toxicity.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S. Kaur, H. A. Kenny, S. Jagadeeswaran, M. R. Zillhardt, A. G. Montag, E. Kistner, S. D. Yamada, A. K. Mitra, and E. Lengyel
{beta}3-Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer
Am. J. Pathol., November 1, 2009; 175(5): 2184 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E.-M. Nothelfer, S. Zitzmann-Kolbe, R. Garcia-Boy, S. Kramer, C. Herold-Mende, A. Altmann, M. Eisenhut, W. Mier, and U. Haberkorn
Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer
J. Nucl. Med., March 1, 2009; 50(3): 426 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
O. ENGEBRAATEN, M. TRIKHA, S. JUELL, S. GARMAN-VIK, and O. FODSTAD
Inhibition of In Vivo Tumour Growth by the Blocking of Host {alpha}v{beta}3 and {alpha}IIb{beta}3 Integrins
Anticancer Res, January 1, 2009; 29(1): 131 - 137.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, K. L. Fink, T. Mikkelsen, T. F. Cloughesy, A. O'Neill, S. Plotkin, M. Glantz, P. Ravin, J. J. Raizer, K. M. Rich, et al.
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
J. Clin. Oncol., December 1, 2008; 26(34): 5610 - 5617.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
I. Burvenich, S. Schoonooghe, L. Vervoort, C. Dumolyn, E. Coene, L. Vanwalleghem, J. Van Huysse, M. Praet, C. Cuvelier, N. Mertens, et al.
Monoclonal antibody 14C5 targets integrin {alpha}v{beta}5
Mol. Cancer Ther., December 1, 2008; 7(12): 3771 - 3779.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Veeravagu, Z. Liu, G. Niu, K. Chen, B. Jia, W. Cai, C. Jin, A. R. Hsu, A. J. Connolly, V. Tse, et al.
Integrin {alpha}v{beta}3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Clin. Cancer Res., November 15, 2008; 14(22): 7330 - 7339.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. MacDonald, C. F. Stewart, M. Kocak, S. Goldman, R. G. Ellenbogen, P. Phillips, D. Lafond, T. Y. Poussaint, M. W. Kieran, J. M. Boyett, et al.
Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012
J. Clin. Oncol., February 20, 2008; 26(6): 919 - 924.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. J. Beer, M. Niemeyer, J. Carlsen, M. Sarbia, J. Nahrig, P. Watzlowik, H.-J. Wester, N. Harbeck, and M. Schwaiger
Patterns of {alpha}v{beta}3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET
J. Nucl. Med., February 1, 2008; 49(2): 255 - 259.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. P. Kelly, F. T. Lee, F. E. Smyth, M. W. Brechbiel, and A. M. Scott
Enhanced Efficacy of 90Y-Radiolabeled Anti-Lewis Y Humanized Monoclonal Antibody hu3S193 and Paclitaxel Combined-Modality Radioimmunotherapy in a Breast Cancer Model
J. Nucl. Med., April 1, 2006; 47(4): 716 - 725.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. J. DeNardo
Combined Molecular Targeting for Cancer Therapy: A New Paradigm in Need of Molecular Imaging
J. Nucl. Med., January 1, 2006; 47(1): 4 - 5.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Belvisi, T. Riccioni, M. Marcellini, L. Vesci, I. Chiarucci, D. Efrati, D. Potenza, C. Scolastico, L. Manzoni, K. Lombardo, et al.
Biological and molecular properties of a new {alpha}v{beta}3/{alpha}v{beta}5 integrin antagonist
Mol. Cancer Ther., November 1, 2005; 4(11): 1670 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Miers, K. Lamborn, A. Yuan, C. Richman, A. Natarajan, S. DeNardo, and G. DeNardo
Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?
Clin. Cancer Res., October 1, 2005; 11(19): 7158s - 7163s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al.
Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy
Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.